RxDoctor Payments Data

Heather Bryce

Family · Huntsville, ALNPI 1982729588

Payments from drug & device makers

$8,072in general payments, 2019–2025

Across 382 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Bayer$730
  • Lilly USA, LLC$583
  • GSK$561
  • Astellas Pharma US Inc$287
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$8,071100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,072 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$165,956
FarxigaDapagliflozin Propanediol76$78,258
JardianceEmpagliflozin64$72,950
Synjardy XrEmpagliflozin/Metformin Hcl45$61,981
RybelsusSemaglutide21$59,621
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$58,646
MounjaroTirzepatide32$48,888
JanuviaSitagliptin Phosphate26$38,892
EliquisApixaban31$38,563
Tresiba Flextouch U-200Insulin Degludec27$37,120
VascepaIcosapent Ethyl31$23,772
XareltoRivaroxaban26$21,770
Trijardy XrEmpaglifloz/Linaglip/Metformin20$20,598
MyrbetriqMirabegron15$17,520
Janumet XrSitagliptin Phos/Metformin Hcl15$11,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,940$225,577127 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy$136$165,245149 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,471$86,84589 claims
GSKTrelegy Ellipta$561$58,64677 claims
Lilly USA, LLCMounjaro$583$48,88832 claims
PfizerEliquis$18$38,56331 claims
Astellas Pharma US IncMyrbetriq$287$17,52015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →